A new oestrogen receptor protein target

Ponatinib for CML and Philadelphia chromosome-positive acute lymphoblastic leukaemia

Quizartinib for FLT3-ITD positive AML after second-line chemo or stem cell transplant

HDAC inhibitors sensitise triple-negative breast cancer cells to PARP inhibition and cisplatin treatment

Targeted therapies for colorectal cancer

Highlights from the 4th EUTROC meeting

Interplay between pathologies of ovarian cancer and genomics

Biology of molecular sub types in ovarian cancer

Early stage biomarkers in ovarian cancer

Development of future cancer treatments

Advances in the treatment of colorectal cancer

Effectiveness of PARP inhibitors in ovarian cancer